Entrada Therapeutics, Inc. cotiza a 5.50 USD y tiene una capitalización bursátil de $214M. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -509.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.01 | $-0.95 | $-0.94 |
| Estimado | $-0.99 | $-1.04 | $-1.02 | $-1.16 |
| Sorpresa | — | +2.9% | +6.9% | +19.0% |
| Métrica | TRDA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -621.1% | -38.6% | -582.5% |
| Net Margin | -565.5% | -33.6% | -531.9% |
| FCF Margin | -509.6% | -13.9% | -495.8% |
| ROE | -47.0% | -40.4% | -6.6% |
| ROA | -38.1% | -32.0% | -6.1% |
| Current Ratio | 12.53 | 2.84 | +9.69 |
| Debt / Equity | — | 0.28 | — |